New and emerging HDAC inhibitors for cancer treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24382387.
- Also identified by DOI 10.1172/JCI69738 and PMC identifier 3871231.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner proteins has driven the rapid development of small-molecule inhibitors that target the cancer epigenome. Herein, we discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis. We examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.
Medical subject headings
- Antineoplastic Agents
- Histone Deacetylase Inhibitors
- Neoplasms